ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

HOWL vs IBIO // DIVIDEND YIELD & FCF PAYOUT SAFETY

Werewolf Therapeutics Inc. (NASDAQ) VS. iBio Inc. (NASDAQ) • 15-METRIC TALLY: HOWL 1 — IBIO 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HOWL VS. IBIO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC HOWL IBIO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 77.80% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety ACTIVE 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 4/9 -1.00 IBIO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 57.9 40.8 +17.10 HOWL /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $51.0M $51.4M -$410.4K IBIO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR HOWL REV IBIO REV HOWL GROSS % IBIO GROSS % HOWL FCF IBIO FCF
FY 2025 $169.9M $400.0K — — -$60.3M -$15.3M
FY 2024 $206.1M $225.0K — — -$56.4M -$18.8M
FY 2023 $113.4M $82.2M — — -$32.6M -$30.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HOWL // BETA —
IBIO // BETA —